Millennium Pharmaceuticals Inc. and Abbott Laboratories are confident that they can triple the success rate of compounds in the clinic to 30%. Thus of an estimated 15 products that will enter the clinic over the next five years under their obesity and diabetes deal announced last week, the companies expect to produce four to five marketed products.

The companies expect two or three products to move into the clinic next year and another two to three products per year after that. ABT estimated that the first product would hit the market in 2007 or 2008.